

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
CompanyJazz Pharmaceuticals (zanidatamab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
 Addenbrookes Liver Transplant Association AMMF - The Cholangiocarcinoma Charity Black Health Agency for Equality British Liver Trust Cancer 52 Cancer Black Care Gene People Genetic Alliance UK GUTS UK Helen Rollason Cancer Charity 	 Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation
 Independent Cancer Patients Voice Liver4Life LIVErNorth Macmillan Cancer Support Maggie's Centres Marie Curie 	 NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Scottish Society of Gastroenterology Welsh Government
 Pelican Cancer Foundation PSC Support South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care 	 Comparator companies AS Kalceks (oxaliplatin) Hospira (fluorouracil) Medac (fluorouracil, folinic acid, oxaliplatin) Ranbaxy (oxaliplatin)
Healthcare professional groupsAssociation of Cancer Physicians	Seacross Pharmaceuticals (oxaliplatin)
 Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Association for the Study of the Liver British Geriatrics Society British Hepatology Pharmacy Group British Oncology Pharmacy Association British Psychosocial Oncology Society 	Relevant research groups Cochrane Hepato-Biliary Group Foundation for Liver Research Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research

Final stakeholder list for the evaluation of zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] Issue date: May 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society of Gastroenterology British Transplantation Society Cancer Research UK NHS Blood and Transplant Primary Care Society for Gastroenterology Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	NHS Genomic Medicine Service Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388] Issue date: May 2025



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.